FRONT PAGE AMPYRA AUBAGIO AVONEX BETASERON COPAXONE EXTAVIA
Stan's Angels MS News Channel on YouTube GILENYA NOVANTRONE REBIF RITUXAN TECFIDERA TYSABRI
 Daily News for Neuros, Nurses & Savvy MSers: 208,152 Viewers, 8,368 Stories & Studies
Click Here For My Videos, Advice, Tips, Studies and Trials.
Timothy L. Vollmer, MD
Department of Neurology
University of Colorado Health Sciences Center Professor

Co-Director of the RMMSC at Anschutz Medical Center

Medical Director-Rocky Mountain MS Center
Click here to read my columns
Brian R. Apatoff, MD, PhD
Multiple Sclerosis Institute
Center for Neurological Disorders

Associate Professor Neurology and Neuroscience,

Weill Medical College of Cornell University

Clinical Attending in Neurology,
New York-Presbyterian Hospital
CLICK ON THE RED BUTTON BELOW
You'll get FREE Breaking News Alerts on new MS treatments as they are approved
MS NEWS ARCHIVES: by week

HERE'S A FEW OF OUR 6000+ Facebook & MySpace FRIENDS
Timothy L. Vollmer M.D.
Department of Neurology
University of Colorado Health Sciences Center
Co-Director of the RMMSC at Anschutz Medical Center
and
Medical Director-Rocky Mountain MS Center


Click to view 1280 MS Walk photos!

"MS Can Not
Rob You of Joy"
"I'm an M.D....my Mom has MS and we have a message for everyone."
- Jennifer Hartmark-Hill MD
Beverly Dean

"I've had MS for 2 years...this is the most important advice you'll ever hear."
"This is how I give myself a painless injection."
Heather Johnson

"A helpful tip for newly diagnosed MS patients."
"Important advice on choosing MS medication "
Joyce Moore


This page is powered by Blogger. Isn't yours?

Wednesday

 

GeneFo Partners with MitoQ to Offer Energy Supplement at Discount to MS Community




























GeneFo, a social-medical community that connects patients with multiple sclerosis (MS) and offers free in-house medical consulting, recently announced a partnership with MitoQ, a New Zealand-based company focused on mitochondrial health. MitoQ is a mitochondria-targeted antioxidant supplement that may help to alleviate common symptoms in MS.

MS, a chronic disease of the central nervous system, is associated with the formation of focal myelin loss and progressive neurodegeneration. Recent evidence indicates that defects in the mitochondria, as well as mitochondrial structural and functional changes, may contribute to disease development and progression.

Scientists studying the role of mitochondria in MS believe that mitochondrial defects impact cellular pathways to cause such processes as inflammation and demyelination, leading to MS symptoms. (Mitochondria produce energy in cells through a process of cellular respiration.)

In a recent review, “Inflammation, Iron, Energy Failure, and Oxidative Stress in the Pathogenesis of Multiple Sclerosis,” published in the journal Oxidative Medicine and Cellular Longevity, Dr. Lukas Haider at the Medical University of Vienna wrote, “Recent data indicate that mitochondrial injury and subsequent energy failure are key factors in the induction of demyelination and neurodegeneration.”

The brain accounts for about 20 percent of the total basal oxygen consumption of mitochondria. Brain cells are susceptible to oxidative stress, which has been found to induce mitochondrial injury in patients with MS and energy failure in the central nervous system of susceptible individuals. Without properly functioning mitochondria, brain cells cannot thrive. For this reason, mitochondria-targeted antioxidants such as MitoQ aim to address oxidative stress by decreasing mitochondrial oxidative damage.

MitoQ is reported to help reduce fatigue, improve brain function, and decrease muscle exhaustion, as reported by patients, according to a news release provided by GeneFo to Multiple Sclerosis News Today: “ Within the first month of use, I noticed an improvement in energy. I was less foggy and was able to get through the day without being so tired. It also helped with my cognitive function and was a little bit clearer.”

Through the collaboration between GeneFo and MitoQ, MS patients are being offered a 20 percent discount on the retail price of the supplement.

“The partnership with MitoQ is not a commercial one, and GeneFo is not to gain any revenue from it. Rather, our motivation, as a medical platform, is to highlight resources/products that could benefit our Multiple Sclerosis community, and secure it for the lowest price possible,” Adi Bein, a vice president at GeneFo, said. “With MitoQ, we have repeatedly heard from both patients and researchers that the product seems to help patients with energy, mobility, and mental functions — so it was really important for us to try help our patients have easier financial access to the product, and we hope this exclusive 20% reduction off retail prices comes in handy for community members.”

Story Source: The above story is based on materials provided by MULTIPLESCLEROSISNEWSTODAY
Note: Materials may be edited for content and length
Click here to read more

Labels:



Go to Newer News Go to Older News